Using only the clinical criteria of severity to select patients when CD4 is not available would be an appropriate strategy (similar diagnostic yield of LAM); however, it would exclude a proportion of patients (one quarter in our study) who could benefit from the test. This evidence concerns the gene CD4 and lymphangioleiomyomatosis.